REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

21 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

14 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

06 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

09 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

29 مايو 2024 16:45:48 بحسب Nasdaq GlobeNewswire

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

28 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the BIO International Convention

21 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

15 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

14 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

13 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

09 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

15 أبريل 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

15 أبريل 2024 08:05:00 بحسب Nasdaq GlobeNewswire

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

28 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

26 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Present at the UBS Virtual CNS Day

11 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Present at the 36th Annual ROTH Conference

07 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

20 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

06 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

25 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire